Cognition Therapeutics releases topline data from Phase 2 COG1201 SHIMMER study

COGNITION THERAPEUTICS INC

Slide presentation on topline results from Phase 2 COG1201 SHIMMER study made available as Exhibit 99.1.
Study evaluates lead candidate for Alzheimer's disease; no specific data points disclosed in the 8-K body.
Filing dated December 18, 2024; presentation likely includes efficacy/safety findings but details are unreadable.
Company undertakes no obligation to update the materials; investor attention should review the full presentation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.